London · Delayed Price · Currency is GBP · Price in USD Esperion Therapeutics Company Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States.
The company’s marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.
Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C.
It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH.
Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
| Country | United States |
| Founded | 2008 |
| Industry | Medical - Pharmaceuticals |
| Sector | Healthcare |
| Employees | 304 |
| CEO | Sheldon Koenig |
Contact Details
Address: 3891 Ranchero Drive Ann Arbor, Delaware 48108 United States | |
| Phone | 734 887 3903 |
| Website | esperion.com |
Stock Details
| Ticker Symbol | 0IIM |
| Exchange | London Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US29664W1053 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Sheldon Koenig | Chief Executive Officer |
| Benjamin Halladay | Chief Financial Officer |